[go: up one dir, main page]

CO2019011547A2 - Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol - Google Patents

Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol

Info

Publication number
CO2019011547A2
CO2019011547A2 CONC2019/0011547A CO2019011547A CO2019011547A2 CO 2019011547 A2 CO2019011547 A2 CO 2019011547A2 CO 2019011547 A CO2019011547 A CO 2019011547A CO 2019011547 A2 CO2019011547 A2 CO 2019011547A2
Authority
CO
Colombia
Prior art keywords
pyrazol
pyridin
hydrochloride
propyl
phenyl
Prior art date
Application number
CONC2019/0011547A
Other languages
English (en)
Inventor
Sung Hwan Moon
Soo Jin Lee
Sung Chan Lee
Original Assignee
Aptabio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptabio Therapeutics Inc filed Critical Aptabio Therapeutics Inc
Publication of CO2019011547A2 publication Critical patent/CO2019011547A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con un clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1H-pirazol-5-ol cristalino novedoso, un método para preparar el compuesto, y una composición farmacéutica que contiene el compuesto como un ingrediente activo.
CONC2019/0011547A 2017-04-20 2019-10-17 Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol CO2019011547A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170050924A KR101856444B1 (ko) 2017-04-20 2017-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물
PCT/KR2018/004604 WO2018194416A1 (ko) 2017-04-20 2018-04-20 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물

Publications (1)

Publication Number Publication Date
CO2019011547A2 true CO2019011547A2 (es) 2020-02-18

Family

ID=62184173

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011547A CO2019011547A2 (es) 2017-04-20 2019-10-17 Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol

Country Status (14)

Country Link
US (1) US11174240B2 (es)
EP (1) EP3613733B1 (es)
JP (1) JP6982097B2 (es)
KR (1) KR101856444B1 (es)
CN (1) CN110678455B (es)
AU (1) AU2018256259B2 (es)
CA (1) CA3060046C (es)
CL (1) CL2019002986A1 (es)
CO (1) CO2019011547A2 (es)
ES (1) ES2924798T3 (es)
MX (1) MX2019012454A (es)
PL (1) PL3613733T3 (es)
RU (2) RU2754255C2 (es)
WO (1) WO2018194416A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101840702B1 (ko) * 2017-11-01 2018-03-22 압타바이오 주식회사 간질환 치료제
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
CN114746079A (zh) * 2019-11-21 2022-07-12 三进制药株式会社 用于预防或治疗眼部疾病的滴眼剂组合物
KR102308991B1 (ko) * 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
MX2022012472A (es) * 2020-04-08 2022-12-15 Aptabio Therapeutics Inc Agente para el tratamiento de lesion renal aguda inducida por medio de contraste.
EP4137134A4 (en) * 2020-04-13 2024-08-07 Aptabio Therapeutics Inc. MEDICATION AGAINST PULMONARY FIBROSIS CONTAINING A PYRAZOLE DERIVATIVE
KR102589130B1 (ko) * 2021-03-24 2023-10-13 삼진제약주식회사 N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179282C (no) * 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US8637674B2 (en) 2009-09-02 2014-01-28 Ewha University-Industry Collaboration Foundation Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
KR101280160B1 (ko) * 2009-09-02 2013-06-28 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR20120098489A (ko) * 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물
KR20120098462A (ko) 2011-02-28 2012-09-05 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
KR101633957B1 (ko) 2012-08-27 2016-06-27 이화여자대학교 산학협력단 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물
TW201603849A (zh) 2014-07-01 2016-02-01 賽諾菲公司 響片配置及其藥物輸送裝置

Also Published As

Publication number Publication date
US11174240B2 (en) 2021-11-16
MX2019012454A (es) 2019-12-19
RU2021116820A (ru) 2021-06-22
WO2018194416A1 (ko) 2018-10-25
BR112019022002A2 (pt) 2020-05-12
RU2019132946A (ru) 2021-04-19
AU2018256259A1 (en) 2019-11-07
JP2020517661A (ja) 2020-06-18
RU2019132946A3 (es) 2021-04-19
ES2924798T3 (es) 2022-10-11
EP3613733A4 (en) 2020-11-18
CA3060046C (en) 2021-08-31
EP3613733A1 (en) 2020-02-26
CN110678455A (zh) 2020-01-10
RU2754255C2 (ru) 2021-08-31
CN110678455B (zh) 2022-08-16
US20210122726A1 (en) 2021-04-29
JP6982097B2 (ja) 2021-12-17
PL3613733T3 (pl) 2022-09-26
CL2019002986A1 (es) 2020-01-24
KR101856444B1 (ko) 2018-05-10
EP3613733B1 (en) 2022-07-20
CA3060046A1 (en) 2018-10-25
AU2018256259B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
MY195977A (en) Heterocyclic Compounds and uses Thereof
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
MX381735B (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
HUE049437T2 (hu) Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
EA201691741A1 (ru) Фармацевтическая композиция
MX2020005564A (es) Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
EA202090732A1 (ru) Составы для трансдермального введения
MX390480B (es) Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX2020009412A (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.